Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability.
Research Tissue Bank for people with MPN
This study allows for the preservation and/or storage of a small portion one or more of the following tissues:
Bone marrow biopsy;
A phlebotomized unit of blood;
The goals of this research study are to understand the causes of MPDs. Learn more.